Chiltern Develops Functional Service Model Relationships in Western Europe
London, UK-September 3, 2009
Chiltern International Limited, a global clinical research organization (CRO) has been selected as the sole provider of clinical research staff for the monitoring aspect of all clinical research projects for Western Europe for a top pharmaceutical company.
All CRAs will be seconded via Chiltern’s European Resourcing Solutions team and fully allocated to the company under a Functional Service or FSP model. The Chiltern CRAs will work directly with the client Project Managers.
Another leading pharmaceutical company also selected Chiltern as the sole provider of an FSP relationship within their pharmacovigilance team. FSP relationships are gaining popularity in the industry due to the flexibility in resource allocations and the cost savings they can offer to clients.
“These are great achievements for Chiltern,” commented Linda Christmas, Chiltern Executive Vice President, Resourcing Solutions, “and helps us meet our target to develop strategically aligned relationships with our clients. We are delighted that we have been able to partner with two more leading pharmaceutical companies in two different core functions.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
